. >> vemos el huracan john que t esta abriendose paso aÑl pkl ppo ifacidfic pacifico. >> vemos que elo no esta tocando tierra a asi que podmeos emos estar tanq coranquilos comn las condiciones secas. >> no tte la ps precipitacicip a las temperaturas con los 3 dig digitos para el staran poe r im0 en los proximos dias. >> ( musica ) >> ahora eelo barato puede sal c caro. >> al continuacion en contacto t deportes los dewtalles aÑl un n continuar con la paisusa . >> ademas telemundo esta disp i disponibo para ipad, iphone y android. >> ( musica ) >> ♪ (musica) continuamos comon esta gran i a iniciativa donde telemundo 48 y ayudara a miles de esrtudiantu d de el area de la bahia ayudare ayudaremayudarememos a los papas y a los estuiddiate apotayando a sus escuelas. >> que tal amigos buenas yattar. >> aqui vemos una de las kjugads mas importantes de la confere conferencia de 1971- >> doijeron que le rendiran h r honores a las estrellas que m murieron en el mes de junio. >> veremos tambien las grandes j jugadas. >> aqui vemos que este jugador s salto muy aktolto en esos tiemp. >> esta rindie

i would say that regardless of whether it was a hide adaptable plan or a regular ppo plan, you do not have the financial incentive. high-cost claims are a major driver overall. they are becoming high-cost claims. you look at some of these drugs that are emerging, whether it is because of the drug and the administration of the drug. this coming together of pharmacy and high-cost claims. i think employers are really , how do youout manage those high-cost specialty pharmacy drugs. that is one of those in the mix of high-cost claims. cancer is in the category, related to drugs. it is a high-cost claim category. out -- getng to get at some of these. 30%-40% of companies will offer cancer coe's next year. that is one of the better ways to get out of high cost claims. alright. other questions? going once. going twice. alright, thank you all very much. [captions copyright national cable satellite corp. 2017] [captioning performed by the national captioning institute, which is responsible for its caption content and accuracy. visit ncicap.org] >> this week, a panel of former clerks to supreme

fast forward to today where whether you have a high deductible plan or a ppo the deductible is still pretty high in the consumer is paying first dollar coverage, rebates don't work well in that environment. there are a lot of reasons employers don't like rebates. part of it is it is a convoluted approach to lower drug costs from their perspective. the difference between gross and net in terms of what somebody could pay versus what the net price could be. there has to be a more simplified approach to how you manage cost and the rebates structure, and into the market for the perverse nature of -- there is a lot of complexity in this model, it is not just about pbms, if price goes up in pharmacy and stakeholders benefit. and we are getting at this model. >> there are market opportunities, why doesn't that exists? >> you have new pbm entrance that are more transparent models. look at pbms today, 70% to 80% more of the market. it is not the easiest market, it is not the easiest model to break into. not a model that is under construction. we may be getting to a tipping deka where you see c

so nice as for today where whether you have a high deductible plan or you're in a a ppo, the deductible is probably still pretty high and the consumers bank first dollar coverage. rebates don't really work well in that environment and so i think there are a lot of reasons employers don't like rebates. part of it is it's very conflict approach to try to lower drug costs from their perspective. the difference between gross and net insurance in terms of whaty could pay versus what the net price could be. there's got to be a more simplified approach to how you manage cost, and actually the rebate structure can also prevent some of the drugs from coming into the market because of the perverse nature of rebates and formula and the like. so there's a lot of complexity in this model that is not just about pbms or just about manufacturers or just about distributors. when price goes up in pharmacy, all the stakeholders benefit and we have to find a different way of getting this model. >> there would seem to be market opportunity for pharma claims process that wouldn't play games and deals strictl